Cautious stance maintained, despite performance upgrade
25/11/21 -"Despite all the good work so far by Novo’s management, we maintain our cautious stance on the Danish diabetes giant. Lack of (medium-term) growth drivers outside the maturing diabetes market, ..."
Pages
72
Language
English
Published on
25/11/21
You may also be interested by these reports :
20/02/26
After incorporating the 2025 financials, we have added a new forecast year to our model, which expects a continuation of growth at Novartis. The firm ...
20/02/26
Expanding margins despite moderate topline growth
18/02/26
After Bayer announced that it will settle most of the Roundup (glyphosate; herbicide) related class action suits (alleging Non-Hodgkin’s lymphoma, a ...
18/02/26
Genmab’s full-year 2025 results showed both sales and adjusted operating profit falling short of market expectations. Despite this, double-digit ...